Cardiovascular Revascularization Medicine最新文献

{"title":"Complete fracture and retrieval of the delivery system of GORE cardioform atrial septal defect occluder during transcatheter closure","authors":"Akihito Tanaka ,&nbsp;Kenji Furusawa ,&nbsp;Yoshiyuki Tokuda ,&nbsp;Masato Mutsuga ,&nbsp;Toyoaki Murohara","doi":"10.1016/j.carrev.2025.04.034","DOIUrl":"10.1016/j.carrev.2025.04.034","url":null,"abstract":"<div><div>The Gore® Cardioform ASD<span> Occluder (GCA) was recently introduced for the transcatheter closure of atrial septal defects in clinical practice. Properly aligning the GCA device with the atrial septum is sometimes challenging, and the tip of the device delivery system is sometimes hand-shaped for better alignment. In this report, we present a complete fracture of GCA delivery system during deployment when using the bending technique. This phenomenon should be considered when using this device.</span></div></div>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"79 ","pages":"Pages 106-107"},"PeriodicalIF":1.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144055977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The AltaValve system for transcatheter mitral valve replacement: A narrative review of early safety and efficacy data","authors":"Michail Penteris","doi":"10.1016/j.carrev.2025.06.008","DOIUrl":"10.1016/j.carrev.2025.06.008","url":null,"abstract":"<div><div>Mitral regurgitation<span><span><span> (MR) is a prevalent and progressive condition associated with poor outcomes in high-risk patients who are often ineligible for surgery or transcatheter repair. The AltaValve system (4C Medical Technologies<span>, Maple Grove, MN), a novel transcatheter mitral valve replacement<span> (TMVR) device, employs a unique supra-annular, atrial-only fixation mechanism designed to minimize left ventricular outflow tract (LVOT) obstruction and paravalvular leak. This narrative review summarizes current clinical evidence on AltaValve, including case reports, single-center, and multicenter experiences, as well as findings from the recent AltaValve Early Feasibility Study. Across diverse patient populations, such as those with functional, primary, and atrial MR, the device has demonstrated high technical success, favorable safety, and significant reduction in MR severity. Transseptal delivery has emerged as a less invasive and safer approach compared to transapical access, further expanding the device's applicability. Short-term follow-up reveals consistent improvement in </span></span></span>hemodynamics<span>, functional capacity, and quality of life measures, with low procedural complication rates. No cases of valve </span></span>embolization, significant thrombosis, or structural degeneration have been reported yet. While early outcomes are promising, the data are limited to small, non-randomized cohorts, and long-term durability remains to be established. The AltaValve system represents a significant step forward in TMVR, particularly for patients with anatomically complex or inoperable MR. Ongoing pivotal trials will be essential to confirm its role within the transcatheter valve therapy landscape.</span></div></div>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"79 ","pages":"Pages 112-119"},"PeriodicalIF":1.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144318385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term clinical efficacy of transfemoral transcatheter aortic valve implantation with three different platforms","authors":"Elena Dipietro ,&nbsp;Giuliano Costa ,&nbsp;Mariachiara Calì ,&nbsp;Orazio Strazzieri ,&nbsp;Silvia Crescenzia Motta ,&nbsp;Valentina Frittitta ,&nbsp;Alessandro Comis ,&nbsp;Sofia Sammartino ,&nbsp;Luigi La Rosa ,&nbsp;Carmelo Sgroi ,&nbsp;Wanda Deste ,&nbsp;Pierfrancesco Veroux ,&nbsp;Salvatore Lentini ,&nbsp;Maria Cristina Inserra ,&nbsp;Maria Teresa Cannizzaro ,&nbsp;Valeria Garretto ,&nbsp;Corrado Tamburino ,&nbsp;Marco Barbanti","doi":"10.1016/j.carrev.2025.01.014","DOIUrl":"10.1016/j.carrev.2025.01.014","url":null,"abstract":"<div><h3>Background</h3><div>Long-term durability and outcomes of transcatheter aortic valve implantation (TAVI) have been reported only with first generation devices.</div></div><div><h3>Objectives</h3><div>To compare clinical efficacy of TAVI with Sapien 3 (Edwards Lifesciences), Evolut R/PRO (Medtronic) or Acurate Neo (Boston Scientific) transcatheter heart valves (THVs) at long-term.</div></div><div><h3>Methods</h3><div>Consecutive TAVI patients treated with Sapien 3, Evolut R/PRO and Acurate Neo THVs at Policlinico G. Rodolico of Catania with at least 5 years follow-up were included in this analysis. Patients were divided into three different groups according to the TAVI device used. Outcomes were compared after inverse probability of treatment weighting adjustment. The primary endpoint was the composite of all-cause death, disabling stroke and heart failure (HF) re-hospitalization at 7 years. The co-primary endpoint was valve-related clinical efficacy according to Valve Academic Research Consortium 3 (VARC-3) definition, at 7 years.</div></div><div><h3>Results</h3><div>From September 2014 to December 2018, 383 tranfemoral TAVI patients receiving Sapien 3 (<em>n</em> = 131, 34.2 %), Evolut R/PRO (<em>n</em> = 134, 34.9 %), or Acurate Neo (<em>n</em> = 118, 30.8 %) devices were compared. At 7 years, the composite primary endpoint did not differ among study groups (60.2 % vs. 51.6 % vs. 62.1 % for Sapien 3, Evolut R/PRO and Acurate Neo, respectively, p_log-rank = 0.50). The co-primary endpoint was also similar (2.2 % vs. 1.2 % vs. 4.2 %, for Sapien 3, Evolut R/PRO and Acurate Neo, respectively, p_log-rank = 0.86).</div></div><div><h3>Conclusions</h3><div><span>Clinical efficacy of TAVI with Sapien 3, Evolut R/PRO and Acurate Neo devices was sustained and comparable up to 7 years. Low and similar rates of valve degeneration were reported among the three devices. Randomized clinical trials are necessary to corroborate these findings and to assess the impact of specific </span>hemodynamic differences among the three THV platforms in the context of long-term clinical efficacy.</div></div>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"79 ","pages":"Pages 24-30"},"PeriodicalIF":1.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143477148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of transcatheter aortic valve replacement in heart failure patients: Insights from the National Readmission Database","authors":"Ahmed M. Younes ,&nbsp;Ahmed K. Mahmoud ,&nbsp;Ibrahim Kamel ,&nbsp;Hossam Albeyoumi ,&nbsp;Ahmed Maraey ,&nbsp;Mahmoud Khalil","doi":"10.1016/j.carrev.2025.03.002","DOIUrl":"10.1016/j.carrev.2025.03.002","url":null,"abstract":"<div><h3>Background</h3><div><span>The effect of ejection fraction on outcomes after </span>transcatheter aortic valve replacement (TAVR) in heart failure (HF) patients remains unclear.</div></div><div><h3>Methods</h3><div><span>Using the National Readmission Database (2016–2020), adult HF patients who underwent TAVR were identified, and outcomes were compared between those with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF). The primary outcome was all-cause inpatient mortality, while secondary outcomes included major bleeding, packed red blood cell (pRBC) transfusion, </span>acute kidney injury<span> (AKI), ischemic cerebrovascular accidents (CVA), valvular complications, conversion to open surgery, length of stay, and total charges.</span></div></div><div><h3>Results</h3><div><span>Among 231,092 HF patients who underwent TAVR, 89,782 had HFrEF. Compared to HFpEF patients, HFrEF was associated with higher inpatient mortality (adjusted odds ratio [aOR] 1.97, 95 % CI 1.78–2.19, </span><em>P</em> &lt; 0.001), major bleeding (aOR 1.49, 95 % CI 1.36–1.63, <em>P</em> &lt; 0.001), pRBC transfusion (aOR 1.28, 95 % CI 1.19–1.38, <em>P</em> &lt; 0.001), AKI (aOR 1.89, 95 % CI 1.79–1.99, <em>P</em> &lt; 0.001), valvular complications (aOR 1.41, 95 % CI 1.21–1.64, P &lt; 0.001), and conversion to open surgery (aOR 1.72, 95 % CI 1.28–2.34, P &lt; 0.001), with no significant difference in ischemic CVA (aOR 1.12, 95 % CI 0.97–1.29, <em>P</em> = 0.13). HFrEF was also associated with longer hospital stays (adjusted mean difference [aMD] 2.06 days, 95 % CI 1.93–2.18, <em>P</em> &lt; 0.001) and higher total charges (aMD $29,783, 95 % CI 25,106–34,460, P &lt; 0.001).</div></div><div><h3>Conclusion</h3><div>Patients with HFrEF undergoing TAVR experienced worse outcomes compared to those with HFpEF. These findings underscore the need for meticulous patient selection and risk evaluation before performing TAVR in HF patients.</div></div>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"79 ","pages":"Pages 41-44"},"PeriodicalIF":1.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145195938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors of permanent pacemaker implantation after TAVI with Navitor transcatheter heart valve","authors":"Matteo Casenghi ,&nbsp;Sara Corradetti ,&nbsp;Stefano Rigattieri ,&nbsp;Francesca Giovannelli ,&nbsp;Marta Belmonte ,&nbsp;Marco Redivo ,&nbsp;Carlo Terrone ,&nbsp;Daniele Barzetti ,&nbsp;Antonella Tommasino ,&nbsp;Eric Wyffels ,&nbsp;Emanuele Gallinoro ,&nbsp;Raffaella Mistrulli ,&nbsp;Pasquale Paolisso ,&nbsp;Andrea Berni ,&nbsp;Marc Vanderheyden ,&nbsp;Emanuele Barbato","doi":"10.1016/j.carrev.2025.04.039","DOIUrl":"10.1016/j.carrev.2025.04.039","url":null,"abstract":"<div><h3>Aims</h3><div><span>This study aimed to identify predictors of permanent pacemaker implantation (PPI) within 30 days after </span>transcatheter aortic valve implantation<span> (TAVI) using the Navitor™ (Abbott Chicago, IL, USA) transcatheter heart valve (THV).</span></div></div><div><h3>Methods and results</h3><div><span>This retrospective two-center study included 173 patients with severe aortic stenosis<span> undergoing transfemoral TAVI with Navitor™ THV. Patients with prior pacemaker implantation and valve-in-valve procedures were excluded. Mean age was 81.5 ± 5.0 years, and 54 patients (31 %) required PPI; they were more often male (57 % vs. 37 %, </span></span><em>p</em><span> = 0.01), had higher left ventricular ejection fraction (55.3 ± 9.0 vs. 52.4 ± 9.2, </span><em>p</em><span> = 0.049), and higher rates of COPD (30 % vs. 16 %, </span><em>p</em><span> = 0.017) and pre-existing right bundle branch block (RBBB; 17 % vs. 0.8 %, </span><em>p</em> &lt; 0.001). Procedural factors associated with PPI included greater annulus-to-THV oversizing (13.6 % ± 3.4 vs. 12.5 % ± 3.1, <em>p</em> = 0.041), implantation depth &gt; 4 mm (75.9 % vs. 52.1 %, <em>p</em> = 0.002), and 29 mm valve size use (46.3 % vs. 26.9 %, <em>p</em> = 0.010). At multivariable analysis, COPD (OR 2.4, <em>p</em> = 0.049), pre-existing RBBB (OR 34.4, <em>p</em> = 0.001), annulus-to-THV oversizing (OR 1.2, <em>p</em> = 0.002), and implantation depth &gt; 4 mm (OR 3.2, <em>p</em> = 0.007) were independent predictors of PPI. ROC analysis (AUC 0.58) identified an optimal cut-off of 15 % annulus-to-THV oversizing for predicting PPI.</div></div><div><h3>Conclusions</h3><div>Annulus-to-THV oversizing emerges as a novel independent predictor for PPI after TAVI with Navitor™ THV.</div></div>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"79 ","pages":"Pages 45-51"},"PeriodicalIF":1.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144051038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reintervention after aortic root replacement with allograft, xenograft, and stented bioprosthetic valves","authors":"Takuya Ogami ,&nbsp;Derek Serna-Gallegos ,&nbsp;Floyd W. Thoma ,&nbsp;Danny Chu ,&nbsp;Johannes O. Bonatti ,&nbsp;Pyongsoo D. Yoon ,&nbsp;David J. Kaczorowski ,&nbsp;Ibrahim Sultan","doi":"10.1016/j.carrev.2024.12.020","DOIUrl":"10.1016/j.carrev.2024.12.020","url":null,"abstract":"<div><h3>Background</h3><div><span>There has been a significant increase in the utilization of non-mechanical valves in the aortic position over time. However, details in reinterventions after aortic root replacement (ARR) with non-mechanical prosthesis were limited in the literature, despite the potential importance of reinterventions in the lifetime management of </span>aortic valve disease.</div></div><div><h3>Methods</h3><div><span>This is a single-center retrospective study, identifying all patients who underwent ARR with allograft, </span>xenografts<span>, and stented bioprosthetic valved conduit from 2010 to 2020. Cumulative incidence was plotted for aortic valve reintervention.</span></div></div><div><h3>Results</h3><div>A total of 523 patients underwent ARR with non-mechanical valves: allograft (<em>n</em> = 80, 15.3 %), xenograft (<em>n</em> = 267, 51.1 %), and stented bioprosthetic valved conduit (<em>n</em><span> = 176, 33.7 %). The mean age was 65.9 years old. A history of infective endocarditis was seen in 124 (23.7 %). Overall, valve reintervention was observed in 21 (4.0 %). The median time to reintervention was 4.77 years. The reason for valve reintervention included structural valve deterioration (</span><em>n</em> = 12), followed by infective endocarditis (<em>n</em><span> = 6), complication during mitral valve replacement (</span><em>n</em><span><span> = 1), cardiac mass (n = 1), and pseudoaneurysm (n = 1). None of the reinterventions were transcatheter-based. Expected reintervention rates were 8.1 ± 2.0 % at 10 years. Cox hazard regression analysis revealed </span>ejection fraction &lt;30 and heart failure were independently associated with long-term mortality while type of valve was not.</span></div></div><div><h3>Conclusions</h3><div>Aortic valve reintervention was infrequent. Although subsequent valve in valve transcatheter intervention is often discussed when implanting non-mechanical valves, it was not a common strategy after ARR in our experience. The type of valve was not related to long-term mortality.</div></div>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"79 ","pages":"Pages 13-17"},"PeriodicalIF":1.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145195937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"One-year hemodynamic and clinical outcomes in self-expanding valves: Comparison of ACURATE neo2 versus ACURATE neo","authors":"Yoichi Sugiyama ,&nbsp;Hirokazu Miyashita ,&nbsp;Sebastian Dahlbacka ,&nbsp;Tommi Vähäsilta ,&nbsp;Tiina Vainikka ,&nbsp;Mikko Jalanko ,&nbsp;Juho Viikilä ,&nbsp;Mika Laine ,&nbsp;Noriaki Moriyama","doi":"10.1016/j.carrev.2024.12.008","DOIUrl":"10.1016/j.carrev.2024.12.008","url":null,"abstract":"<div><h3>Background/purpose</h3><div>Transcatheter aortic valve replacement (TAVR) with ACURATE neo2 showed better hemodynamic outcomes by mitigating paravalvular leakage (PVL) compared with ACURATE neo, and revealed promising one-year outcomes in single-arm studies. However, studies comparing the hemodynamic and clinical outcomes of the two valves are still scarce. Therefore, this study aimed to compare the one-year hemodynamic and clinical outcomes between the neo2 and neo.</div></div><div><h3>Methods/materials</h3><div>We analyzed 562 patients who underwent TAVR with ACURATE neo2 (n = 207) or ACURATE neo (n = 355). The primary outcome was one-year all-cause mortality. The secondary outcomes were hemodynamic outcomes at hospital discharge, 3-month, and one-year post-procedure.</div></div><div><h3>Results</h3><div>In propensity score matching comparison (172 pairs), there was no significant difference in one-year all-cause mortality between the two groups (neo2: 7.0 % vs. neo: 6.4 %, Log-rank <em>p</em> = 0.8101). While the mean aortic valve pressure gradient was significantly higher in the neo2 group at discharge, the difference was not detected after one year (8.1 ± 3.8 mmHg vs. 8.2 ± 3.7 mmHg, <em>p</em> = 0.8862). The PVL grade did not differ between the two groups at any time point. However, the incidence of moderate or severe PVL significantly decreased at one-year post-procedure compared with that at discharge only in the neo2 group (discharge: 7.2 % vs. one year: 1.5 %, <em>p</em> = 0.0455).</div></div><div><h3>Conclusions</h3><div>The one-year all-cause mortality rate for ACURATE neo2 was similar to that of ACURATE neo. ACURATE neo2 showed the subsequent improvement of significant PVL, which might result in better long-term clinical outcomes than ACURATE neo.</div></div><div><h3>Summary for annotated table of contents</h3><div>This study compared one-year all-cause mortality and hemodynamic outcomes after TAVR between ACURATE neo2 and ACURATE neo implantation. One-year all-cause mortality rate and significant improvement in the mean APG after TAVR for ACURATE neo2 were similar to those of ACURATE neo. ACURATE neo2 revealed the subsequent improvement of significant PVL for one year, which might result in better long-term clinical outcomes than ACURATE neo.</div></div>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"79 ","pages":"Pages 54-60"},"PeriodicalIF":1.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142899173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical implications of cerebral microbleeds in patients who undergo transcatheter aortic valve replacement","authors":"Yusuke Uemura ,&nbsp;Akihito Tanaka ,&nbsp;Yuta Ozaki ,&nbsp;Shogo Yamaguchi ,&nbsp;Takashi Okajima ,&nbsp;Takayuki Mitsuda ,&nbsp;Shinji Ishikawa ,&nbsp;Kenji Takemoto ,&nbsp;Toyoaki Murohara ,&nbsp;Masato Watarai","doi":"10.1016/j.carrev.2024.12.013","DOIUrl":"10.1016/j.carrev.2024.12.013","url":null,"abstract":"<div><h3>Background</h3><div><span>The prognostic implications of cerebral microbleeds (CMBs) in patients who undergo transcatheter aortic valve replacement (TAVR) have not been fully elucidated. Therefore, we aimed to investigate the association between the presence of CMBs and </span>adverse outcomes post-TAVR.</div></div><div><h3>Methods</h3><div>In this single-center retrospective study, we included 124 patients who underwent brain magnetic resonance imaging before TAVR. The outcomes of interest were the subsequent incidences of stroke and all-cause death or admission for heart failure.</div></div><div><h3>Results</h3><div>CMBs were identified in 32.2 % of the included patients. The median follow-up duration was 954 (interquartile range, 553–1306) days. The incidence of stroke after TAVR was comparable between patients with and without CMBs. Conversely, all-cause death or admission for heart failure was significantly higher in patients with CMBs than in those without (log-rank <em>P</em><span> = 0.010). Multivariate Cox regression analysis revealed that the presence of CMBs was independently correlated with the occurrence of all-cause death or admission for heart failure after adjusting for other prognostic predictors (hazard ratio 4.016, 95 % confidence interval 1.572–10.259, </span><em>P</em> = 0.007).</div></div><div><h3>Conclusion</h3><div>The presence of CMBs predicts the incidence of all-cause death or admission for heart failure in patients undergoing TAVR. Evaluating CMBs could provide useful information for post-TAVR management.</div></div>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"79 ","pages":"Pages 8-12"},"PeriodicalIF":1.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142928297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Revascularization strategies for coronary artery aneurysms: A systematic review","authors":"Magdi Zordok ,&nbsp;Kevin G. Buda ,&nbsp;Muhammad Etiwy ,&nbsp;Mir B. Basir ,&nbsp;Khaldoon Alaswad ,&nbsp;Erik Beckmann ,&nbsp;Emmanouil S. Brilakis ,&nbsp;Michael Megaly","doi":"10.1016/j.carrev.2025.03.022","DOIUrl":"10.1016/j.carrev.2025.03.022","url":null,"abstract":"","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"79 ","pages":"Pages 108-111"},"PeriodicalIF":1.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144021337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial: Concomitant transcatheter edge-to-edge repair of mitral and tricuspid regurgitation","authors":"Chirag Bavishi","doi":"10.1016/j.carrev.2025.06.024","DOIUrl":"10.1016/j.carrev.2025.06.024","url":null,"abstract":"","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"79 ","pages":"Pages 104-105"},"PeriodicalIF":1.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144530362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}